Cartesian Therapeutics Inc [RNAC] stock is trading at $19.67, up 3.36%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The RNAC shares have gain 7.14% over the last week, with a monthly amount glided 3.80%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Cartesian Therapeutics Inc [NASDAQ: RNAC] stock has seen the most recent analyst activity on December 19, 2024, when BTIG Research initiated its Buy rating and assigned the stock a price target of $42. On July 02, 2024, downgrade downgraded it’s rating to Perform. Oppenheimer started tracking the stock assigning a Outperform rating and suggested a price target of $50 on June 04, 2024. Mizuho initiated its recommendation with a Buy and recommended $40 as its price target on May 24, 2024. H.C. Wainwright reiterated a Buy rating for this stock on April 23, 2024, and upped its price target to $54. In a note dated April 23, 2024, Leerink Partners initiated an Outperform rating and provided a target price of $39 on this stock.
Cartesian Therapeutics Inc [RNAC] stock has fluctuated between $11.66 and $41.87 over the past year. Currently, Wall Street analysts expect the stock to reach $42.67 within the next 12 months. Cartesian Therapeutics Inc [NASDAQ: RNAC] shares were valued at $19.67 at the most recent close of the market. An investor can expect a potential return of 116.93% based on the average RNAC price forecast.
Analyzing the RNAC fundamentals
Cartesian Therapeutics Inc [NASDAQ:RNAC] reported sales of 47.94M for the trailing twelve months, which represents a drop of -94.09%. Gross Profit Margin for this corporation currently stands at 0.99% with Operating Profit Margin at -1.12%, Pretax Profit Margin comes in at -5.5%, and Net Profit Margin reading is -5.11%. To continue investigating profitability, this company’s Return on Assets is posted at -0.54, Equity is 1.49 and Total Capital is -0.12. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 19.48.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 19.10 points at the first support level, and at 18.54 for the second support level. However, for the 1st resistance point, the stock is sitting at 20.06, and for the 2nd resistance point, it is at 20.46.
Ratios To Look Out For
For context, Cartesian Therapeutics Inc’s Current Ratio is 10.70. Further, the Quick Ratio stands at 10.70, while the Cash Ratio is 10.24. Considering the valuation of this stock, the price to sales ratio is 10.56, the price to book ratio is 625.04.
Transactions by insiders
Recent insider trading involved SPRINGER TIMOTHY A, Director, that happened on Jan 13 ’25 when 16945.0 shares were purchased. Director, SPRINGER TIMOTHY A completed a deal on Jan 14 ’25 to buy 4022.0 shares. Meanwhile, Chief Technology Officer Kurtoglu Metin sold 2458.0 shares on Jan 06 ’25.
